As­traZeneca's block­buster Fasen­ra fails on one of two PhI­II eosinophilic esophagi­tis tri­al end­points

As­traZeneca has been look­ing to give it­self an edge against oth­er ri­val treat­ments in eosinophilic in­di­ca­tions, such as GSK’s Nu­cala, but an ini­tial read­out from …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER